MARTINSRIED, GERMANY and MUNCHEN, GERMANY--(Marketwire - October 12, 2011) -
MorphoSys AG /
MorphoSys AG : AbD Serotec, Moredun Research Institute and Roslin Institute
Announce Grant Funding to Establish Veterinary Research Reagents
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today
itsAbD Serotec business unit entered into an agreement with the Moredun
Institute and the Roslin Institute at The University of Edinburgh to
broad range of research reagents in the veterinary research arena. The
is funded through an Industrial Partnership Award from the
Biological Sciences Research Council (BBSRC) under a joint initiative
Scottish Government's Rural and Environment Science and Analytical
Division (RESAS). Over the three-year term of the grant, the Moredun
Institute and Roslin Institute combined will receive funding of nearly
The primary goal of the collaboration is to develop research reagents to
immunity in ruminant farm animals. Basic research in this area is
inhibited by the lack of species-specific reagents, such as
recombinant cytokines. AbD Serotec has preferred access to
rights for products generated during the collaboration.
"We consider ourselves to be the leading supplier of reagents for
research purposes, and this alliance will help us expand our veterinary
thereby maintaining that position," commented Dieter Feger, Head of AbD
"Today's news also shows our commitment to develop cutting edge
collaboration with renowned research organizations."
The Moredun Research Institute in Scotland is committed to promoting
health and welfare through research and education and is recognized
for its contribution to research into infectious diseases of farmed
Moredun's research has led to the development of many vaccines, diagnostic
and improved treatment strategies for farm animals across the globe.
Professor Gary Entrican from the Moredun Research Institute (and
Professor at the Roslin Institute) commented: "This project will allow
enhance the current knowledge about how immune systems are
regulated in sheep and cattle. This work will help identify the
correlates of protection to many different diseases of cattle and sheep,
for the development of new and improved vaccines. We are excited to be
in partnership with AbD Serotec to advance this area of research and
the distribution of veterinary immunological reagents to the wider
MorphoSys developed HuCAL, the most successful antibody library technology
the pharmaceutical industry. By successfully applying this and other
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Company's AbD Serotec unit uses HuCAL and other technologies to generate
superior monoclonal antibodies for research and diagnostic applications.
Through its own development efforts and successful partnerships in
pharmaceutical industry, MorphoSys has built a therapeutic pipeline of more
70 human antibody drug candidates for the treatment of cancer,
arthritis, and Alzheimer's disease, to name just a few. With its
commitment to new antibody technology and drug development, MorphoSys is
on engineering the medicines of tomorrow. MorphoSys is listed on the
Stock Exchange under the symbol MOR. For regular updates about MorphoSys,
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®
arYla® are registered trademarks of MorphoSys.
About Roslin Institute:
The Roslin Institute (www.roslin.ed.ac.uk) is incorporated with the Royal
School of Veterinary Studies, the world leading Veterinary School in the
the 2008 Research Assessment Exercise, at the University of
Institute undertakes research within the framework of BBSRC Institute
Programmes focussed on the health and welfare of animals, and
basic animal sciences in human and veterinary medicine, the livestock
and food security. The Roslin Institute received a total of £8.5M
from the Biotechnology and Biological Sciences Research Council in 2010-11.
This communication contains certain forward-looking statements
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the
assumptions, actual results and actions may differ from those
MorphoSys does not intend to update any of these forward-looking
far as the wording of the relevant press release is concerned.
--- End of Message ---
Lena-Christ-Str. 48 Martinsried / München Germany
WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Media Release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE